RV7 Stock Overview
A biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Halozyme Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$55.42 |
| 52 Week High | US$58.18 |
| 52 Week Low | US$35.18 |
| Beta | 1.25 |
| 1 Month Change | 1.95% |
| 3 Month Change | 21.59% |
| 1 Year Change | 47.04% |
| 3 Year Change | 73.62% |
| 5 Year Change | 242.10% |
| Change since IPO | 2,430.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| RV7 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0.9% | -1.6% | 0.5% |
| 1Y | 47.0% | -15.9% | 14.7% |
Return vs Industry: RV7 exceeded the German Biotechs industry which returned -15.9% over the past year.
Return vs Market: RV7 exceeded the German Market which returned 14.7% over the past year.
Price Volatility
| RV7 volatility | |
|---|---|
| RV7 Average Weekly Movement | 3.6% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: RV7 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: RV7's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 350 | Helen Torley | halozyme.com |
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product.
Halozyme Therapeutics, Inc. Fundamentals Summary
| RV7 fundamental statistics | |
|---|---|
| Market cap | €7.00b |
| Earnings (TTM) | €426.46m |
| Revenue (TTM) | €975.02m |
16.4x
P/E Ratio7.2x
P/S RatioIs RV7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RV7 income statement (TTM) | |
|---|---|
| Revenue | US$1.02b |
| Cost of Revenue | US$238.47m |
| Gross Profit | US$776.86m |
| Other Expenses | US$332.77m |
| Earnings | US$444.09m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.61 |
| Gross Margin | 76.51% |
| Net Profit Margin | 43.74% |
| Debt/Equity Ratio | 413.9% |
How did RV7 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/03 21:43 |
| End of Day Share Price | 2025/02/28 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Halozyme Therapeutics, Inc. is covered by 35 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| James Birchenough | Barclays |
| Robert Wasserman | Benchmark Company |